Is screening for pancreatic cancer in high-risk groups cost-effective? Experience from a Danish national screening program

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Is screening for pancreatic cancer in high-risk groups cost-effective? Experience from a Danish national screening program. / Jøergensen, Maiken Thyregod; Gerdes, Anne-Marie; Sørensen, Jan; Schaffalitzky de Muckadell, Ove; Mortensen, Michael Bau.

I: Pancreatology, Bind 16, Nr. 4, 2016, s. 584-92.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Jøergensen, MT, Gerdes, A-M, Sørensen, J, Schaffalitzky de Muckadell, O & Mortensen, MB 2016, 'Is screening for pancreatic cancer in high-risk groups cost-effective? Experience from a Danish national screening program', Pancreatology, bind 16, nr. 4, s. 584-92. https://doi.org/10.1016/j.pan.2016.03.013

APA

Jøergensen, M. T., Gerdes, A-M., Sørensen, J., Schaffalitzky de Muckadell, O., & Mortensen, M. B. (2016). Is screening for pancreatic cancer in high-risk groups cost-effective? Experience from a Danish national screening program. Pancreatology, 16(4), 584-92. https://doi.org/10.1016/j.pan.2016.03.013

Vancouver

Jøergensen MT, Gerdes A-M, Sørensen J, Schaffalitzky de Muckadell O, Mortensen MB. Is screening for pancreatic cancer in high-risk groups cost-effective? Experience from a Danish national screening program. Pancreatology. 2016;16(4):584-92. https://doi.org/10.1016/j.pan.2016.03.013

Author

Jøergensen, Maiken Thyregod ; Gerdes, Anne-Marie ; Sørensen, Jan ; Schaffalitzky de Muckadell, Ove ; Mortensen, Michael Bau. / Is screening for pancreatic cancer in high-risk groups cost-effective? Experience from a Danish national screening program. I: Pancreatology. 2016 ; Bind 16, Nr. 4. s. 584-92.

Bibtex

@article{20a317c76f934afcba0888b0b3071a60,
title = "Is screening for pancreatic cancer in high-risk groups cost-effective?: Experience from a Danish national screening program",
abstract = "OBJECTIVE: Pancreatic cancer (PC) is the fourth leading cause of cancer death worldwide, symptoms are few and diffuse, and when the diagnosis has been made only 10-15% would benefit from resection. Surgery is the only potentially curable treatment for pancreatic cancer, and the prognosis seems to improve with early detection. A hereditary component has been identified in 1-10% of the PC cases. To comply with this, screening for PC in high-risk groups with a genetic disposition for PC has been recommended in research settings.DESIGN: Between January 2006 and February 2014 31 patients with Hereditary pancreatitis or with a disposition of HP and 40 first-degree relatives of patients with Familial Pancreatic Cancer (FPC) were screened for development of Pancreatic Ductal Adenocarcinoma (PDAC) with yearly endoscopic ultrasound. The cost-effectiveness of screening in comparison with no-screening was assessed by the incremental cost-utility ratio (ICER).RESULTS: By screening the FPC group we identified 2 patients with PDAC who were treated by total pancreatectomy. One patient is still alive, while the other died after 7 months due to cardiac surgery complications. Stratified analysis of patients with HP and FPC provided ICERs of 47,156 US$ vs. 35,493 US$ per life-year and 58,647 US$ vs. 47,867 US$ per QALY. Including only PDAC related death changed the ICER to 31,722 US$ per life-year and 42,128 US$ per QALY. The ICER for patients with FPC was estimated at 28,834 US$ per life-year and 38,785 US$ per QALY.CONCLUSIONS: With a threshold value of 50,000 US$ per QALY this screening program appears to constitute a cost-effective intervention although screening of HP patients appears to be less cost-effective than FPC patients.",
keywords = "Adult, Aged, Aged, 80 and over, Cost-Benefit Analysis, Denmark, Early Detection of Cancer, Female, Humans, Incidence, Male, Mass Screening, Middle Aged, Pancreatic Neoplasms, Prognosis, Risk Assessment, Risk Factors, Smoking, Treatment Outcome, Journal Article",
author = "J{\o}ergensen, {Maiken Thyregod} and Anne-Marie Gerdes and Jan S{\o}rensen and {Schaffalitzky de Muckadell}, Ove and Mortensen, {Michael Bau}",
note = "Copyright {\textcopyright} 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.",
year = "2016",
doi = "10.1016/j.pan.2016.03.013",
language = "English",
volume = "16",
pages = "584--92",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Is screening for pancreatic cancer in high-risk groups cost-effective?

T2 - Experience from a Danish national screening program

AU - Jøergensen, Maiken Thyregod

AU - Gerdes, Anne-Marie

AU - Sørensen, Jan

AU - Schaffalitzky de Muckadell, Ove

AU - Mortensen, Michael Bau

N1 - Copyright © 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.

PY - 2016

Y1 - 2016

N2 - OBJECTIVE: Pancreatic cancer (PC) is the fourth leading cause of cancer death worldwide, symptoms are few and diffuse, and when the diagnosis has been made only 10-15% would benefit from resection. Surgery is the only potentially curable treatment for pancreatic cancer, and the prognosis seems to improve with early detection. A hereditary component has been identified in 1-10% of the PC cases. To comply with this, screening for PC in high-risk groups with a genetic disposition for PC has been recommended in research settings.DESIGN: Between January 2006 and February 2014 31 patients with Hereditary pancreatitis or with a disposition of HP and 40 first-degree relatives of patients with Familial Pancreatic Cancer (FPC) were screened for development of Pancreatic Ductal Adenocarcinoma (PDAC) with yearly endoscopic ultrasound. The cost-effectiveness of screening in comparison with no-screening was assessed by the incremental cost-utility ratio (ICER).RESULTS: By screening the FPC group we identified 2 patients with PDAC who were treated by total pancreatectomy. One patient is still alive, while the other died after 7 months due to cardiac surgery complications. Stratified analysis of patients with HP and FPC provided ICERs of 47,156 US$ vs. 35,493 US$ per life-year and 58,647 US$ vs. 47,867 US$ per QALY. Including only PDAC related death changed the ICER to 31,722 US$ per life-year and 42,128 US$ per QALY. The ICER for patients with FPC was estimated at 28,834 US$ per life-year and 38,785 US$ per QALY.CONCLUSIONS: With a threshold value of 50,000 US$ per QALY this screening program appears to constitute a cost-effective intervention although screening of HP patients appears to be less cost-effective than FPC patients.

AB - OBJECTIVE: Pancreatic cancer (PC) is the fourth leading cause of cancer death worldwide, symptoms are few and diffuse, and when the diagnosis has been made only 10-15% would benefit from resection. Surgery is the only potentially curable treatment for pancreatic cancer, and the prognosis seems to improve with early detection. A hereditary component has been identified in 1-10% of the PC cases. To comply with this, screening for PC in high-risk groups with a genetic disposition for PC has been recommended in research settings.DESIGN: Between January 2006 and February 2014 31 patients with Hereditary pancreatitis or with a disposition of HP and 40 first-degree relatives of patients with Familial Pancreatic Cancer (FPC) were screened for development of Pancreatic Ductal Adenocarcinoma (PDAC) with yearly endoscopic ultrasound. The cost-effectiveness of screening in comparison with no-screening was assessed by the incremental cost-utility ratio (ICER).RESULTS: By screening the FPC group we identified 2 patients with PDAC who were treated by total pancreatectomy. One patient is still alive, while the other died after 7 months due to cardiac surgery complications. Stratified analysis of patients with HP and FPC provided ICERs of 47,156 US$ vs. 35,493 US$ per life-year and 58,647 US$ vs. 47,867 US$ per QALY. Including only PDAC related death changed the ICER to 31,722 US$ per life-year and 42,128 US$ per QALY. The ICER for patients with FPC was estimated at 28,834 US$ per life-year and 38,785 US$ per QALY.CONCLUSIONS: With a threshold value of 50,000 US$ per QALY this screening program appears to constitute a cost-effective intervention although screening of HP patients appears to be less cost-effective than FPC patients.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Cost-Benefit Analysis

KW - Denmark

KW - Early Detection of Cancer

KW - Female

KW - Humans

KW - Incidence

KW - Male

KW - Mass Screening

KW - Middle Aged

KW - Pancreatic Neoplasms

KW - Prognosis

KW - Risk Assessment

KW - Risk Factors

KW - Smoking

KW - Treatment Outcome

KW - Journal Article

U2 - 10.1016/j.pan.2016.03.013

DO - 10.1016/j.pan.2016.03.013

M3 - Journal article

C2 - 27090585

VL - 16

SP - 584

EP - 592

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 4

ER -

ID: 177483617